Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.

Diabetes Obes Metab · 2025 · PMC12587239 · PMID 40990044

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The estimated mean difference was very similar between groups at 9 months (about −3 kg; Figure 2B,E ), while weight loss tended to be more pronounced in the oral semaglutide group at 18 months, which was nominally significant for the trial product estimand (−2.6 kg; 95% C.I. from −5.2 to −0.1; Figure 2E ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.